BillionToOne
Founded Year
2016Stage
Debt | AliveTotal Raised
$563.64MValuation
$0000Last Raised
$140M | 21 days agoAbout BillionToOne
BillionToOne is a diagnostics company specializing in molecular diagnostics within the healthcare sector. The company offers proprietary molecular counting technology that enables accurate detection and quantification of disease-related deoxyribonucleic acid at the single base-pair level, primarily for prenatal screening and oncology testing. BillionToOne's technology serves the healthcare industry, with a focus on improving prenatal care and cancer treatment through diagnostic tests. It was founded in 2016 and is based in Menlo Park, California.
Loading...
ESPs containing BillionToOne
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The liquid biopsy cancer screening market offers a non-invasive alternative to traditional tissue biopsies for detecting cancer. This market includes various solutions such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) tests, which can detect cancer at an early stage and monitor treatment effectiveness. The liquid biopsy method is less invasive, faster, and more cost-effectiv…
BillionToOne named as Challenger among 15 other companies, including Exact Sciences, QIAGEN, and Guardant Health.
Loading...
Research containing BillionToOne
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned BillionToOne in 2 CB Insights research briefs, most recently on Dec 5, 2023.
Expert Collections containing BillionToOne
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
BillionToOne is included in 3 Expert Collections, including Digital Health.
Digital Health
11,072 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Women's Health Tech
585 items
This collection includes companies applying technology to address a spectrum of physical, mental, and social well-being concerns specific to women. Examples include companies in reproductive health, maternal care, fertility tracking, and menopause support.
Digital Health 50
50 items
BillionToOne Patents
BillionToOne has filed 13 patents.
The 3 most popular patent topics include:
- molecular biology
- biotechnology
- genetics
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
8/6/2019 | 8/27/2024 | Molecular biology, Transcription factors, Biotechnology, Drug discovery, Gene expression | Grant |
Application Date | 8/6/2019 |
|---|---|
Grant Date | 8/27/2024 |
Title | |
Related Topics | Molecular biology, Transcription factors, Biotechnology, Drug discovery, Gene expression |
Status | Grant |
Latest BillionToOne News
Sep 10, 2024
Med-tech firms raising money in public or private financings, including: Billiontoone, Discure Technologies, Ionopticks, Perimeter Medical Imaging AI, Viome.
BillionToOne Frequently Asked Questions (FAQ)
When was BillionToOne founded?
BillionToOne was founded in 2016.
Where is BillionToOne's headquarters?
BillionToOne's headquarters is located at 1035 O'Brien Drive, Menlo Park.
What is BillionToOne's latest funding round?
BillionToOne's latest funding round is Debt.
How much did BillionToOne raise?
BillionToOne raised a total of $563.64M.
Who are the investors of BillionToOne?
Investors of BillionToOne include Oberland Capital, Hummingbird Ventures, Neotribe Ventures, Libertus Capital, Civilization Ventures and 20 more.
Loading...
Loading...